Cyclin E1 (CCNE1) as independent positive prognostic factor in advanced stage serous ovarian cancer patients - a study of the OVCAD consortium.

Cyclin E, coded by the genes CCNE1 and CCNE2, is the main regulator for transition from G1 to S phase determining cell division. CCNE1 and CCNE2 are known oncogenes in many cancer entities. Especially CCNE1 has frequently been associated with gene amplifications in various malignancies, emphasising its role as a putative oncogene. We determined gene expression and copy number of CCNE1 and CCNE2 by quantitative polymerase chain reaction (PCR) from 172 International Federation of Obstetrics and Gynecology (FIGO) II/III/IV stage serous epithelial ovarian cancer (EOC) tissues and analysed its impact on outcome. Furthermore, whole transcriptome gene expression changes correlating with CCNE1 expression were determined by microarray technology, interpreted by Signalling Pathway Impact Analysis (SPIA), Tool for Inferring Network of Genes (TINGe), and illustrated by hive plots. Protein-protein interaction (PPI) networks were also used for the interpretation. Interestingly, and contradictory to most reports and intuitive expectations, high CCNE1 expression correlated with better overall survival (p=0.005) if corrected for usual clinicopathologic parameters and a molecular subclassification. Using different grading systems or only high graded tumours had no impact on this correlation. Copy number of CCNE1 was increased in 25% of cases which correlated highly significantly with expression but showed no impact on outcome. CCNE2 had no impact on outcomes at all. Whole genome transcriptome analysis revealed 1872 differentially expressed genes correlated to CCNE1 expression, which were significantly enriched with genes from five pathways (e.g. cell cycle and viral carcinogenesis pathway were up-regulated and the Fanconi anaemia pathway was down-regulated). High CCNE1 gene expression is a significant and independent predictor for prolonged overall survival in FIGO III/IV EOC patients. This upside down impact of CCNE1 on survival probably reflects the special characteristic of EOC with tumour dissemination in the near anaerobic peritoneal cavity as the predominant cause of death, compared to other cancer entities where distant metastasis are predominantly lethal.

[1]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[2]  Inanç Birol,et al.  Hive plots - rational approach to visualizing networks , 2012, Briefings Bioinform..

[3]  I. Christensen,et al.  Limited prognostic value of tissue protein expression levels of cyclin E in Danish ovarian cancer patients: from the Danish ‘MALOVA’ ovarian cancer study , 2012, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[4]  James M. Roberts,et al.  Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family , 1991, Cell.

[5]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[6]  Jidong Liu,et al.  Cyclin E2, a novel human G1 cyclin and activating partner of CDK2 and CDK3, is induced by viral oncoproteins , 1998, Oncogene.

[7]  Michael T Deavers,et al.  Grading Ovarian Serous Carcinoma Using a Two-Tier System , 2004, The American journal of surgical pathology.

[8]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[9]  S. Ryser,et al.  Oncogenic BARD1 isoforms expressed in gynecological cancers. , 2007, Cancer research.

[10]  Young Tae Kim,et al.  Alteration of cell-cycle regulation in epithelial ovarian cancer , 2007, International Journal of Gynecologic Cancer.

[11]  P. Kaldis,et al.  Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms , 2009, Oncogene.

[12]  Varda Rotter,et al.  Transcriptional control of the proliferation cluster by the tumor suppressor p53. , 2010, Molecular bioSystems.

[13]  S. Cho,et al.  Significance of Cell Cycle Regulatory Proteins as Malignant and Prognostic Biomarkers in Ovarian Epithelial Tumors , 2011, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[14]  Utpal Banerjee,et al.  Metabolic control of G1–S transition: cyclin E degradation by p53-induced activation of the ubiquitin–proteasome system , 2010, The Journal of cell biology.

[15]  Patrick Royston,et al.  Multivariable Model-Building: A Pragmatic Approach to Regression Analysis based on Fractional Polynomials for Modelling Continuous Variables , 2008 .

[16]  G. Klein,et al.  Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation? , 1998, Oncogene.

[17]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Georg Heinze,et al.  Validating the impact of a molecular subtype in ovarian cancer on outcomes: A study of the OVCAD Consortium , 2012, Cancer science.

[19]  Yuan-li He,et al.  Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer , 2012, Oncology reports.

[20]  Ituro Inoue,et al.  Gene expression profiling of advanced‐stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis , 2009, Cancer science.

[21]  E. Kohn,et al.  Ovarian cancer , 2013, Cancer.

[22]  E. Friedman,et al.  Comparative genomic hybridization in inherited and sporadic ovarian tumors in Israel. , 2000, Cancer genetics and cytogenetics.

[23]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[24]  S. Mok,et al.  Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. , 2006, Cancer research.

[25]  Tobias Müller,et al.  Bioinformatics Applications Note Systems Biology Bionet: an R-package for the Functional Analysis of Biological Networks , 2022 .

[26]  Y. Dong,et al.  Implication of malignancy and prognosis of p27(kip1), Cyclin E, and Cdk2 expression in epithelial ovarian tumors. , 2001, Gynecologic oncology.

[27]  C. Denkert,et al.  Role of TRAP1 and estrogen receptor alpha in patients with ovarian cancer -A study of the OVCAD consortium , 2012, Molecular Cancer.

[28]  Maximina H. Yun,et al.  Understanding the functions of BRCA1 in the DNA-damage response. , 2009, Biochemical Society transactions.

[29]  Joshy George,et al.  Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas , 2009, Clinical Cancer Research.

[30]  Sheila M. Reynolds,et al.  Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. , 2013, Cancer cell.

[31]  F. Speleman,et al.  Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes , 2002, Genome Biology.

[32]  M. Barbacid,et al.  Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.

[33]  G. Mills,et al.  Cyclin E expression is correlated with tumor progression and predicts a poor prognosis in patients with ovarian carcinoma , 2006, Cancer.

[34]  Isabelle Bedrosian,et al.  Cyclin E and survival in patients with breast cancer. , 2002, The New England journal of medicine.

[35]  Peter Kampstra,et al.  Beanplot: A Boxplot Alternative for Visual Comparison of Distributions , 2008 .

[36]  Mark F. Munsell,et al.  Interobserver and Intraobserver Variability of a Two-tier System for Grading Ovarian Serous Carcinoma , 2007, The American journal of surgical pathology.

[37]  E. D. de Vries,et al.  Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis , 2009, British Journal of Cancer.

[38]  J. Diehl,et al.  Nuclear cyclin D1: An oncogenic driver in human cancer , 2009, Journal of cellular physiology.

[39]  R. Zeillinger,et al.  Outcome and Clinical Management of 275 Patients With Advanced Ovarian Cancer International Federation of Obstetrics and Gynecology II to IV Inside the European Ovarian Cancer Translational Research Consortium—OVCAD , 2012, International Journal of Gynecologic Cancer.

[40]  Phil S. Baran,et al.  Cyclin-dependent kinase 8 mediates chemotherapy-induced tumor-promoting paracrine activities , 2012, Proceedings of the National Academy of Sciences.

[41]  M. Aluru,et al.  Reverse engineering and analysis of large genome-scale gene networks , 2012, Nucleic acids research.

[42]  H. Yee,et al.  Expression of cell cycle regulators p57(KIP2), cyclin D1, and cyclin E in epithelial ovarian tumors and survival. , 2001, Human pathology.

[43]  Pooja Mittal,et al.  A novel signaling pathway impact analysis , 2009, Bioinform..

[44]  Theresia Thalhammer,et al.  Prognostic impact of tumor infiltrating CD8+ T cells in association with cell proliferation in ovarian cancer patients - a study of the OVCAD consortium , 2013, BMC Cancer.

[45]  L. Morrison,et al.  Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study. , 2003, Cancer research.

[46]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[47]  K. Milde-Langosch,et al.  Expression and Prognostic Value of the Cell-cycle Regulatory Proteins, Rb, p16MTS1, p21WAF1, p27KIP1, Cyclin E, and Cyclin D2, in Ovarian Cancer , 2003, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.